Oral Presentation
Mesothelioma and pleural disease: from the bench to the bedside
10:45
LATE-BREAKING ABSTRACT: Spontaneous pleurodesis rates in chemotherapy and non-chemotherapy patients undergoing indwelling pleural catheter insertion for malignant pleural effusion
P. Sivakumar(London, United Kingdom)
COI
1
11:00
Biological markers of successful pleurodesis for malignant pleural effusion
I. Psallidas(London, United Kingdom)
COI
2
11:15
Role of tumor derived versican in experimental malignant pleural mesothelioma
A. Pappas(Athens, Greece)
COI
3
11:30
A conditional mouse model of malignant pleural mesothelioma
A. Krontira(Patras, Greece)
COI
4
11:45
Folic acid phenotype (FAP) as superior marker to predict pemetrexed response in pleural mesothelioma
F. Mairinger(Essen, Germany)
COI
5
12:00
Breath analysis by gas chromatography-mass spectrometry can be used to screen for pleural mesothelioma
K. Lamote(Wilrijk, Belgium)
COI
6
12:15
Long-term outcome of patients with non-specific pleuritis on thoracoscopic or ultrasound-guided pleural biopsies
J. Corcoran(Plymouth, United Kingdom)
COI
7
12:30
Retrospective review of VATS (Pleural) negative biopsy and their outcome in a university hospital
S. Leyakathali Khan(Silverdale, United Kingdom)
COI
8
. . .
